The CXCL12/CXCR4 axis has been shown to play important roles in tumorigenesis and in a variety of other pathological conditions. Here we describe the development and characterization of a high-affinity humanized monoclonal antibody specific for CXCL12. The antibody had anti-tumor activity in multiple xenograft and orthotopic tumor models, as single agent or in combination with anti-VEGF antibodies. This antibody is suitable to test the hypothesis that targeting CXCL12 is a valid strategy to treat cancer and inflammatory diseases in humans.
Introduction
CXCL12, also known as Stromal-Derived Factor 1 (SDF1), is a CXC chemokine that binds to two G-protein-coupled receptors, CXCR4 and CXCR7 (reviewed in (1) . It participates in many developmental and physiological processes, including hematopoiesis and angiogenesis. Gene deletion of CXCL12 or CXCR4 results in embryonic lethality at E18.5, with severe developmental defects affecting central nervous system, bone marrow, heart and vascular system (2, 3) . CXCR7 inactivation, on the other hand, appears to affect primarily cardiac development, although defects in neuronal migration have been also noted (4).
CXCL12α the major form present in mice and humans, is highly conserved, as the mouse and human forms differ only in one amino acid (1) . CXCL12α is produced by numerous cell types including macrophages, lymphocytes, endothelial cells and fibroblasts. CXCR4 activates multiple downstream targets, including ERK1/2, AKT and small GTPases of the Rho family (5) . CXCR7, on the other hand, appears to function at least in part by sequestering CXCL12 (4, 6) .
The CXCL12/CXCR4/CXCR7 pathway has also generated considerable interest as a potential therapeutic target given its role in tumor growth, survival, and angiogenesis (1, 7).
CXCL12 levels have been shown to be important in dictating organ-specific metastasis of several cancers (8) . It has been previously reported that CXCL12 autocrine signaling loops, together with TGFβ, initiate and maintain the differentiation of fibroblasts to myofibroblasts and the concurrent mammary tumor promoting phenotype (9, 10) . CXCL12 induces angiogenesis, both in vitro and in vivo, synergistically with VEGF (11) . VEGF, in turn, can regulate expression of CXCR4 in vascular endothelial cells, hematopoietic stem cells and promote invasion in an autocrine manner by regulating CXCR4 on cancer cells (12, 13) . In recent years, it has become clear that CXCR4 + myeloid cells, recruited from the bone marrow into the tumor microenvironment, participate in tumor angiogenesis (14, 15) . Growing evidence also suggests that CXCR7 is involved in several aspects of tumorigenesis and could become an important target for new anti-metastatic and anti-cancer drugs (16) . Recent preclinical data suggests that small molecule inhibitors of the VEGF pathway result in Author Manuscript Published OnlineFirst on June 28, 2013; DOI: 10.1158/1078-0432.CCR- increases in serum CXCL12 levels, which might relate at least in in part to their ability to promote a more invasive tumor phenotype, when administered at high doses (17, 18) .
Induction of CXCL12 has also been shown to cause development of resistance and to favor recurrences upon radiation (19) .
Here we describe a high-affinity anti-CXCL12 antibody that shows anti-tumor activities in multiple mouse and human tumor models, as a single agent or in combination with anti-VEGF antibodies. Our data further validate CXCL12 as a target not only in cancer but also in several inflammation/angiogenesis-related disease models. Hamster immunization and splenic fusion Female Armenian hamsters were hyperimmunized intraperitoneally, twice per week for a total of 12-13 boosts, with 2 μg/animal recombinant human CXCL12α (R&D Systems). Three days after the final boost, splenocytes were fused with cells derived from the murine myeloma cell line P3X63AgU.1 (ATCC).
Materials and Methods

Cell Lines
Hybridomas were selected using methylcellulose-based hypoxanthine-aminopterin-thymidine (HAT) medium (StemCell Technologies, Vancouver, BC, Canada). Ten to fourteen days post-fusion, culture supernatants were collected and screened by direct ELISA as previously described (20) . Positive cell lines were subcloned 4-6 times by limiting dilutions. Those that kept showing consistent activity were scaled up and purified by Protein A affinity chromatography. The eluate was dialyzed against PBS and concentrated. For large-scale antibody purification, HiTrap (Amersham) protein A column chromatography was employed.
Research. Rac GTP activity assay Jurkat cells stimulated with CXCL12α in the absence or presence of anti-CXCL12 antibodies were lysed in RIPA buffer (Sigma) with proteinase (Roche) and phosphatase inhibitor cocktails (Sigma). Lysates were incubated at 4 o C for 2 hrs. with GSThuman p21 activated kinase PBD-coupled glutathione-sepharose beads (Cytoskeleton, Denver, CO), followed by washing with RIPA buffer. Total and GTP-bound Rac1 were detected by western blotting with an antibody against Rac1 (Cell Signaling Technology, Inc, Danvers, MA). syringe. Treatment was started 2 days after tumor cell implantation. At the end of the study, lungs were perfused with PBS, fixed in 10% formalin and visible tumors were counted (21) .
Cell viability assay
In some cases, authenticity of tumors within lungs was confirmed by H&E staining and Bioluminescence Imaging (BLI).
FACS analysis Whole tumors were minced into small pieces, followed by sequential digestion with Media I for 60 min and Media II for 15 min, as previously described (22) .
Single cells were first incubated at room temperature for 10 min with rat anti-mouse Statistical analysis Unless specifically stated, student's t-test was used for all the statistical analyses, and p≤0.05 was considered to be significant. Graphs present mean ± SD.
Results
In vitro characterization of hamster anti-CXCL12α antibodies
Antibodies against both mouse and human CXCL12α were generated in hamsters. antibodies had any effect on migration when tested alone. 30D8 could also bind to CXCL12β and CXCL12γ, as assessed by direct ELISA and CXCL12β-induced Jurkat cell migration (data not shown).
Next, we compared the abilities of various antibodies to block CXCL12α binding to 293-CXCR4 or 293-CXCR7 cells (Fig 1B & C) . Again, 30D8 was the most potent in blocking binding to CXCR4, while all antibodies showed various degrees of inhibitory effect on binding to CXCR7. The inhibition was specific since 30D8 did not affect chemotaxis of isolated mouse bone marrow cells induced by unrelated chemokines such as KC, MIP2 or RANTES ( Fig 1D) .
AMD3100 ( which has an essential role in cytoskeleton remodeling (5) . Jurkat cells showed a marked increase in GTP-bound Rac1 when treated with CXCL12α at 100 ng/ml for 5 mins. 30D8, 18E9 or 46H9 inhibited CXCL12α-induced Rac1 activation in a dose-dependent manner. In the same assay, anti-CXCR4 antibody MAB170 from R&D systems at 200 μg/ml and AMD3100 at 40 μg/ml had moderate effects ( Fig 1E) .
Inhibition of primary tumor growth by 30D8 alone or in combination with anti-VEGF antibody
The mouse lymphoma model EL4 has been shown to be relatively refractory to anti-VEGF antibody therapy in vivo (15, 24, 25) . Single agent 30D8 significantly inhibited EL4
tumor growth compared to the control antibody in C57BL6 mice at a dose as low as 10 mg/kg. Next, we evaluated the effects of 30D8 on growth of Lewis Lung Carcinoma (LLC) cells implanted subcutaneously in C57BL6 mice (25) (Fig 2C) . 30D8, administered on the same day of tumor cell implantation at the dose of 30 mg/kg, resulted in about 50 % inhibition at day 14, which was comparable to that obtained with B20.4.1.1 at 10 mg/kg. Single-agent activity was also observed when 30D8 was given to animals bearing established tumors of ~400 mm 3 (data not shown). An additive effect (p<0.01) was observed when 30D8 was combined with B20.4.1.1. (Fig 2C) . Interestingly, CXCL12α had a significant effect on LLC cell survival in vitro under serum-free conditions. As shown in Fig 2D , about 50 % of the cells in the control group began to die after 24 hrs in culture, whereas cells incubated with as low as 1.6 ng/ml CXCL12α survived as well as those in 10% serum and continued to proliferate ( Fig   2D) . Such effects could be neutralized completely in the presence of 100 μg/ml 30D8.
Inhibition of metastasis using a mouse orthotopic breast cancer model
To investigate the effects of 30D8 on cancer metastasis, 4T1 breast cancer cells transfected with the luciferase gene were orthotopically inoculated in Balb/c mice (44) .
While treatment with 30D8 had no effect on primary tumor growth (Fig 2E) , it resulted in ~60 % reduction in the number of lung cancer nodules at a dose of 10 mg/kg ( Fig 2F) . All lungs in the control group developed metastasis, with an average of 14 nodules, whereas 1/3 of mice treated with 30D8 had no visible lung metastasis and those that did develop lung metastasis had an average of 5 nodules. Combination of 30D8 at 30 mg/kg with B20.4.1.1 at 10 mg/kg further enhanced the inhibitory effect compared to B20.4. confirmed on 7 μm-thick lung paraffin-embedded sections stained with H&E to reveal all cancer nodules not only on the surface of lung but also within lung tissues (data not shown).
Consistent with in vivo observations, CXCL12α had no effect on 4T1 cell proliferation.
However, it significantly stimulated 4T1 cell migration at 10 ng/ml (~4.5 fold increase compared to control) in vitro. Such stimulation could be completely blocked by 50 μg/ml 30D8 (Supplemental Fig 2) .
Effect of 30D8 in Collagen Induced Arthritis (CIA) model
CXCL12α is highly expressed in the synovium of rheumatoid arthritis patients and has been implicated in the recruitment and accumulation of CD4 + memory T cells, B cells to the synovium during the induction phase as well as other myeloid cells and synovial fibroblast during disease onset and development (27). To investigate if 30D8 had any effect in an experimental mouse CIA model (Supplemental Methods), we first injected 30D8 into DBA-1J mice at day 27 following bovine Collagen type II injection (preventive phase). Mouse/hamster chimera 30D8 (ch30D8) was used to avoid immune responses. muTNFRII-IgG2a was used as a positive control (28) . Compared to muTNFRII-IgG2a, ch30D8 at 30 mg/kg was not effective during onset of the disease (day 24-35) but could significantly slow down disease progression at day 35-73 ( Fig 3A) .
To determine whether ch30D8 can inhibit established inflammation, we initiated treatments in cohorts of CIA mice at day 42. ch30D8 monotherapy significantly ameliorated arthritis compared to the control antibody (Fig 3B) . Although treatment with muTNFRII-IgG2a or ch30D8 alone could reduce the clinical score on day 83, the combination was significantly better than each monotherapy at preventing the progression of arthritis in mice with mild disease at enrollment (Fig 3C) . Such combination substantially reduced bone erosive changes in CIA mice, resulting in a considerably higher joint cortical bone volume (JCBV) compared with mice treated with either inhibitor alone (29) (Fig 3D) .
Effects of 30D8 on laser-induced choroidal neovascularization (CNV) in mice
Research. Laser-induced rupture of Bruch's membrane results in choroidal neovascularization in mice (30) . Bone marrow-derived hematopoietic stem cells are known to be incorporated into sites of retinal and choroidal neovascularization (31) . Treatment with 30D8 at 30 mg/kg i.p. resulted in a 50 % reduction of neovascularization not only in prevention (Fig 3E) but also in intervention studies, in which 30D8 was given 48 hrs post laser (Supplemental Methods and Supplemental Fig 3A) . Representative images of CNV in animals treated with various antibodies are shown Supplemental Fig 3B. In both circumstances, 10 mg/kg B20.4.1.1. resulted in >90% inhibition.
Infiltration of macrophages/dendritic cells expressing CX3CR1 is known to occur as early as 8 hrs after laser injury, with a peak at day 2 (32). We used a transgenic mouse model in which one copy of the CX3CR1 gene is replaced by the GFP reporter gene (33) .
Compared to normal eyes, there was a ~20-fold induction in macrophage infiltration in eyes with laser injury. When animals were pre-treated with 30D8 24 hrs prior to laser injury, macrophage/dendritic cell infiltration into the injured sites was significantly reduced compared to the control antibody group (Fig 3F) . Representative images of infiltrating GFP+ cells are shown in Supplemental Fig 3C. 
Generation and characterization of humanized 30D8 (hu30D8)
30D8 was selected for humanization (Supplemental Methods) based on its in vitro and in vivo activities. The alignment of light chain Kappa between hamster 30D8 and hu30D8 is shown in Supplemental Fig 4 (34-37) . hu30D8 bound not only to CXCL12α, but also to CXCL12β and CXCL12γ in direct ELISA. It specifically blocked CXCL12α-and CXCL12β-induced Jurkat cell migration, with an IC 50 of 0.16 μg/ml (~1 nM), which is comparable to both hamster and mouse/hamster chimeric counterparts. Due to a high apparent on-rate and non-specific binding of CXCL12α to the dextran coated sensor chip at high concentration, the affinity for binding to hu30D8 could not be reliably determined using hu30D8 induced dose-dependent inhibition of EL4 tumor growth in C57BL6 mice at 10-50 mg/kg dose range. This effect was comparable to that of its hamster counterpart ( Fig   5A) . When hu30D8 was given in combination with B20.4.1.1., an additive effect was seen (Fig 5B) . hu30D8 also elicited inhibitory effects in the human Calu6 lung carcinoma, a tumor model highly responsive to VEGF blockade (38) . 10 and 30 mg/kg hu30D8 were equally efficacious in this model and resulted in ~50 % tumor growth inhibition, which was statistically significant compared to the control antibody group (p<0.05) (Fig 5C) . There was no tumor shrinkage observed when we combined 30D8 with B20.4.1. (Fig 5D) .
We also tested the activity of hu30D8 as a single agent in other human xenografts, including the A673, BxPC3, HM7, KMS11 and Ovcar-3 models. In general, hu30D8 was less effective on these models compared to Calu6, with 15-30% tumor inhibition achieved at the dose of 30 mg/kg. Based on Taqman analysis, expression levels of CXCL12α and its receptors in human tumor cells in vitro did not correlate with efficacy of hu30D8 in vivo.
Epitope mapping and crystal structure of hu30D8 Fab/human CXCL12α revealed a proteinprotein interaction "hot spot"
We initially sought to identify the epitope in several hamster antibodies, including 30D8, by alanine scanning of CXCL12α (Supplemental methods). This analysis indicated that 
data, CXCL12α processing at N-and C-termini in blood should not affect its binding to 30D8.
To further elucidate the molecular recognition of CXCL12α by 30D8 and the mechanism of inhibition, we determined the crystal structure of hu30D8 Fab in complex with human CXCL12α (Supplemental Methods and Fig 4) . The crystallographic asymmetric unit contains a CXCL12α dimer and two Fab molecules each binding to one CXCL12α monomer (Fig. 4a) . This is consistent with concentration-dependent dimerization of CXCL12α (39) as the crystallization media contains 160 μM CXCL12α (Supplemental Methods) (40) . It also indicates that the antibody does not inhibit CXCL12α dimerization.
The hu30D8 paratope involves all six complementarity determining regions (CDR) (Fig   4b) . The specific interactions at the two Fab-CXCL12α interfaces are essentially identical.
Remarkably, each interface is comprised of residues from only one CXCL12α monomer, suggesting that the antibody can bind the monomeric form of CXCL12α as well. 
Pharmacokinetics of hu30D8
Research. Pharmacokinetic characteristics (PK) of 30D8 were first studied in mice and subsequently in rats and cynomolgus monkeys (Supplemental Methods). Fast clearances were observed following a single dose of 30 mg/kg in Balb c/nude mice for both 30D8 (i.p. Fig   6A) and hu30D8 (i.v. Fig 6E) and in cynomolgus monkeys for hu30D8 (i.v. Fig 6C) . A significant decrease in serum CXCL12α was observed 3 hrs after 30D8 administration in NCr nude mice. This correlated inversely with the serum 30D8 levels (Fig 6B) . Similarly, serum CXCL12a level was undetectable using HM7-embedded nude mice 3 hrs after 30D8 treatment, whereas no significant change was observed by AMD3100 and the control antibody. In the same study, serum VEGF was not affected significantly by any of the treatment (Supplemental Fig 5A) . Furthermore, a PK study was performed using multiple dosing regimen since the animals received 30D8, 3 times/week, in all in vivo models. When 30D8 was given i.p. for 24 consecutive days at 30 mg/kg, 3 times/week in HM7-embedded nude mice, no significant accumulation of the antibody was observed (Supplemental Fig 5B) .
In contrast, hu30D8 had a normal clearance in nude rats at the same dose level (i.v., Fig   6D) . K D for hu30D8 against rat CXCL12α was 154 nM, 80-fold higher compared to CXCL12α from mouse/human CXCL12α measured by Biolayer Interferometry Lower affinity was expected since rat CXCL12α differs from mouse/human CXCL12α at amino acids Asn 44 and Leu
63
, with the former being the most critical residue for hu30D8 binding.
To investigate if epitope contributed to fast clearance, several antibodies raised in hamsters that target different binding epitope in CXCL12α were tested. Although epitopes were different, all these antibodies had similar binding affinity toward CXCL12α and showed similar clearance as 30D8 (Supplemental Fig 6) . , which removes a key interaction with Asn 44 of CXCL12α, showed 1000-fold lower affinity to human CXCL12α and much slower clearance in vivo compared to parental hu30D8 (Fig 6E) . Other mutants such as hu30D8 
Discussion
The CXCL12/CXCR4 signaling axis has been actively explored as a potential drug target (43) . So far, most of the studies focused on the CXCL12 receptor CXCR4 and on small molecule inhibitors targeting CXCR4 (44), although efforts using neutralizing anti-CXCL12 antibodies have been also reported (45, 46 ).
Here we demonstrate efficacy of the anti-CXCL12 antibody 30D8 in several tumors as well as inflammatory models as a single agent, despite a relatively fast clearance. In all models tested, the efficacious doses of 30D8 were higher than those of anti-VEGF Mab B20.4.1.1, but in the same range as DC101, a widely used monoclonal antibody directed against VEGFR2, which is typically administered at 40 mg/kg every three days in mouse models (47) . mRNA levels of CXCL12α and its receptor by human tumor cells could not be used to predict antitumor activity of hu30D8, possibly they were neither representative of the level of protein on the cell surface nor indicative of the level of proteins with designated functions. In fact, a number of CXCR4 isoforms, mutants with varying levels of glycosylation, have been found on the cell surface, with various functions (48, 49) .
Humanization of 30D8 allowed us to investigate PK in cynomolgus monkeys. Such antibodies will also enable safety studies to assess the consequences of long-term CXCL12 blockade. hu30D8 bound to circulating CXCL12α with very high affinity and subsequently blocked CXCL12α binding (free or heparin-bound forms) to both CXCR4 and CXCR7. The contribution of CXCR7 in tumor growth/metastasis in each model could not be addressed in the current study, due to lack of specific inhibitors. AMD3100 was less efficacious in some of our in vivo models, which might be due to its activity as a CXCR7 ligand with allosteric agonist properties (50) . When 30D8 was used in combination with anti-VEGF or a TNFRII-IgG2a fusion protein, efficacy could be further improved, suggesting that CXCL12 could become a novel target at least in subsets of arthritis patients that fail to respond to anti-TNF therapy (27). In the CIA and CNV models, blocking CXCL12 function prevented macrophage and/or lymphocyte infiltration at an early phase, although the current study could not rule out the possibility that 30D8 inhibited angiogenesis by directly inhibiting endothelial cell migration and survival as well.
Preliminary data indicate a greater efficacy of hu30D8 in syngeneic immune-competent mice compared to immune-deficient mice bearing EL4 tumor (data not shown). If CD8 + Tlymphocyte-mediated immune responses were important for anti-tumor activity, then immunodeficient mice would not be expected to fully reveal the efficacy of hu30D8.
In the present study, we observed fast clearance of 30D8 in mice and cynomolgus monkeys. Based on data using hu30D8 mutants, fast clearance appeared to correlate well with affinity of the antibody toward CXCL12α. A preliminary screen using a library of 1000 human secreted proteins indicated that hu30D8 does not non-specifically bind to other secreted proteins (unpublished observations), arguing against the possibility that non-specific binding is a reason for the fast clearance. Likewise, hu30D8 was classified as "low risk" for fast clearance in an assay of non-specific binding shown to be useful for identifying antibodies likely to show fast clearance in cynomolgus monkey (51) . Notably, the crystal structure of hu30D8/human CXCL12α complex revealed that hu30D8 only partially blocks heparin-binding sites on CXCL12α, raising the possibility that target-mediated clearance could be related to heparin binding by CXCL12α. Therefore, balancing PK and binding affinity appears to be a requirement for optimal efficacy of the antibody. Further studies are needed to unravel the mechanism(s) of fast clearance.
In conclusion, hu30D8 is a suitable tool to test the hypothesis that targeting CXCL12 is a valid strategy to treat cancer and inflammatory diseases in humans. The availability of predictive biomarkers to select patients most likely responsive to anti-CXCL12 therapy would be a major step toward the initiation of such human studies. The total and GTP-bound Rac1 were detected by western blotting using an antibody against Rac1. Data was representative of three independent studies. B   310  315  323  333  341  346  357  362  367  370  383  384  394  309  314  320  321  342  351  364  369  372  374  378  379  392  316  324  334  335  338  340  363  366  388  389  393  395  399  307  327  330  332  337  339  349  361  368  371  382  385  396 Clinical score Figure 6 Research. 
